LONDON (Thomson Financial) - Tepnel Life Sciences PLC said it has completed
the phase II construction and launch of biopharmaceutical and clinical
genotyping services at its Livingston facility in Scotland.
The company said the introduction of the services will give Tepnel access to
the rapidly-growing markets in the two areas.
Tepnel's chief executive Ben Matzilevich said the new capabilities are "key
to our long term growth strategy."
tf.TFN-Europe_newsdesk@thomson.com
ro
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|